26 results about "Curcuma zedoaria" patented technology

The application discloses a traditional Chinese medicine composition for treating pregnancy embryo residue, a preparation method and application thereof and a pharmaceutical preparation, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following components: Astragalus membranaceus, Angelica sinensis, Ligusticum chuanxiong, Sparganium stoloniferum, Curcuma zedoaria, Semen Persicae, Herba impatiens, Radix Trichosanthis, Solpugid and Motherwort. Clinical efficacy observation shows that the traditional Chinese medicine composition can effectively promote the discharge of residual tissue, avoid the operation of a palace cleaning operation, shorten the time of vaginal bleeding, promote the repair of endometrium, and has good patient compliance and good tolerance, and no serious adverse reactions are found, and the effective rate is more than 90%. The traditional Chinese medicine composition is based on the theory of monarch, minister and assistant in traditional Chinese medicine, and the components are matched with each other, so that an excellent use effect is achieved.

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating vaginitis, and preparation raw materials of the traditional Chinese medicine composition include zedoary turmeric and Chinese atractylodes rhizome. The traditional Chinese medicine composition can kill common pathogenic bacteria of vaginosis, and has good bacteriostatic effect. While inhibiting the common pathogenic bacteria of vaginosis, the traditional Chinese medicine composition does not inhibit lactobacillus of vagina. The traditional Chinese medicine composition can not only kill single common pathogenic bacteria of vaginosis, but also relieve trichomonas vaginalis, and inhibit mixed infection of bacteria and fungi.

This invention discloses a pharmaceutical composition and its preparation method for treating atrophic gastritis, precancerous lesions of the stomach, and stomach cancer, belonging to the field of traditional Chinese medicine preparation technology. The pharmaceutical composition is prepared by a specific two-step microbial fermentation process using Astragalus membranaceus, Hericium erinaceus, Curcuma zedoaria, Actinidia chinensis root, Camptotheca acuminata fruit, Hedyotis diffusa, Coptis chinensis, Taraxacum mongolicum, Viola yedoensis, Corydalis yanhusuo (processed with vinegar), Phellodendron chinense, Solanum nigrum, Scutellaria baicalensis, Panax notoginseng, Zingiber officinale, Piper cubeba, Cuttlebone, Fritillaria thunbergii, roasted soybean, and red yeast rice. This invention significantly improves the bioavailability of the active pharmaceutical ingredients through the synergistic effect of the multifunctional groups of traditional Chinese medicine and the enhanced effect of microbial fermentation. It can systematically reverse gastric mucosal atrophy and intestinal metaplasia, effectively improve microcirculation, and inhibit Helicobacter pylori, while also exhibiting good safety. This provides a novel and effective treatment for the aforementioned gastric diseases.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

This invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis and its application, belonging to the field of traditional Chinese medicine technology. The traditional Chinese medicine composition for treating chronic atrophic gastritis provided by this invention is made from the following raw materials in parts by weight: 15-25 parts of Salvia miltiorrhiza, 8-16 parts of Curcuma zedoaria (processed with vinegar), 2-6 parts of Eupolyphaga sinensis, 10-20 parts of Codonopsis pilosula, 8-16 parts of Dendrobium nobile (dried), 5-15 parts of Pinellia ternata (processed), 1-5 parts of Evodia rutaecarpa (processed), and 1-5 parts of Coptis chinensis. It has the effects of promoting blood circulation and removing blood stasis, strengthening the spleen and replenishing qi, nourishing yin and benefiting the stomach, inhibiting bacteria and inflammation, and regulating immunity. It is suitable for chronic atrophic gastritis, especially those with gastric blood stasis combined with stomach yin deficiency or spleen and stomach weakness. It can significantly repair the gastric mucosa and reverse atrophic intestinal metaplasia, and is safe and reliable, providing a new traditional Chinese medicine treatment for chronic atrophic gastritis.

This invention discloses a traditional Chinese medicine composition for treating tumors and its preparation method, belonging to the field of traditional Chinese medicine technology. The composition comprises *Uncaria rhynchophylla*, *Prunella vulgaris*, *Astragalus membranaceus*, *Adenophora stricta*, *Ophiopogon japonicus*, *Fritillaria thunbergii*, *Curcuma zedoaria*, *Panax notoginseng*, *Atractylodes macrocephala* (fried), *Ligustrum lucidum*, *Eclipta prostrata*, and *Glycyrrhiza uralensis* (processed). The formula focuses on clearing heat and detoxifying, resolving phlegm and dissipating nodules, strengthening the body's resistance, and promoting blood circulation and removing blood stasis. It combines tonification and purgation, addressing both the root cause and symptoms, precisely targeting the core pathogenesis of tumors: deficiency of vital energy, phlegm accumulation, blood stasis, and toxin accumulation. It can inhibit tumor cell proliferation, dissipate masses, enhance the body's immunity, reduce adverse reactions to radiotherapy and chemotherapy, improve clinical symptoms, stabilize tumors, and delay tumor progression and recurrence / metastasis, showing promising clinical application prospects.

This invention discloses a traditional Chinese medicine composition for treating liver fibrosis with damp-heat toxicity, comprising the following raw materials in parts by weight: 20-30 parts of processed turtle shell, 18-25 parts of Oldenlandia diffusa, 11-15 parts of Curcuma zedoaria, 20-30 parts of processed Salvia miltiorrhiza (wine-processed), 14-20 parts of Scutellaria barbata, 11-15 parts of Epimedium, 10-15 parts of Artemisia capillaris, 14-20 parts of Sedum sarmentosum, 7-10 parts of Bupleurum chinense, 7-10 parts of Curcuma longa, 6-8 parts of dried ginger, 11-15 parts of stir-fried Atractylodes macrocephala, 18-25 parts of Astragalus membranaceus, 7-10 parts of Prunus persica, 8-12 parts of Schisandra chinensis, 4-6 parts of Panax notoginseng (powder), 14-20 parts of Poria cocos, and 3-5 parts of Cinnamomum cassia. This traditional Chinese medicine composition is developed based on the principles of TCM syndrome differentiation and treatment for liver fibrosis with damp-heat toxicity, and has the expected therapeutic effect on this condition.

The application discloses a primer, a kit and a method for identifying Curcuma plants, and belongs to the technical field of species identification. The method comprises the following steps: (1) extracting DNA from Curcuma plants to be identified; (2) using the DNA obtained in step (1) as a template, performing PCR amplification on the template by using 26 pairs of primers to obtain amplification products; (3) performing fluorescence capillary electrophoresis detection on the amplification products obtained in step (2); and (4) analyzing the detection results obtained in step (3) by using data analysis software, performing cluster analysis on sample genotype data obtained in the analysis, determining whether the Curcuma plants to be identified can be clustered into one category with the Curcuma plants in a cluster map, and distinguishing different individuals of the Curcuma plants according to a cluster result. The primer and the kit can be used to realize rapid identification of the Curcuma plants, and can be used to identify Curcuma kwangsiensis, C. zedoaria, C. longa, C. wenyujin, C. rotundifolia and C. aromatica.

This invention discloses a blood-nourishing and kidney-tonifying pill for treating lower back pain due to kidney yin deficiency, prepared from the following Chinese medicinal herbs in parts by weight: 25-35 parts Rehmannia glutinosa, 20-30 parts Cornus officinalis, 18-22 parts Eucommia ulmoides, 15-25 parts Achyranthes bidentata, 20-30 parts Angelica sinensis, 22-30 parts Ligusticum chuanxiong, 20-28 parts Salvia miltiorrhiza, 15-25 parts Curcuma zedoaria, 20-30 parts Citrus reticulata peel, 10-20 parts Cyperus rotundus, 15-25 parts Bupleurum chinense, and 20-30 parts Atractylodes macrocephala. The formula contains 0 parts of Rehmannia glutinosa, 15-25 parts of Citrus aurantium, 18-22 parts of Amomum villosum, 20-30 parts of Scutellaria baicalensis, 15-25 parts of Morus alba root bark, 10-20 parts of bitter apricot kernel, and 15-25 parts of Eriobotrya japonica leaf. The whole formula contains Rehmannia glutinosa, Cornus officinalis, Eucommia ulmoides, Achyranthes bidentata, Angelica sinensis, Ligusticum chuanxiong, Salvia miltiorrhiza, Curcuma zedoaria, Citrus reticulata peel, Cyperus rotundus, Bupleurum chinense, Atractylodes macrocephala, Citrus aurantium, Amomum villosum, Scutellaria baicalensis, Morus alba root bark, bitter apricot kernel, and Eriobotrya japonica leaf. It nourishes blood and tonifies the kidneys to treat kidney yin deficiency and lower back pain, and its preparation method is disclosed.

This invention discloses a traditional Chinese medicine composition for pulmonary nodules and its preparation method. The composition is prepared from the following components in parts by weight: 6-30 parts raw oyster shell, 3-15 parts Scrophularia ningpoensis, 3-15 parts Fritillaria thunbergii, 2-10 parts Uncaria rhynchophylla, 3-15 parts vinegar-processed turtle shell, 3-15 parts stir-fried Bombyx mori, 2-10 parts stir-fried mustard seed, 2-10 parts processed Pinellia ternata, 3-15 parts Codonopsis pilosula, 2-10 parts vinegar-processed Curcuma zedoaria, 3-15 parts Rhodiola rosea, 2-10 parts bee honeycomb, 6-30 parts lily bulb, 3-15 parts dried plum, 3-15 parts Ganoderma lucidum, 2-10 parts stir-fried bitter almond, 3-15 parts honey-processed mulberry bark, and 2-10 parts Scutellaria baicalensis. This invention has the functions of resolving phlegm and removing blood stasis, attacking toxins and dispersing nodules, invigorating qi and promoting qi circulation, and nourishing yin and moistening the lungs. It is used in medicines and health products for pulmonary nodules.

This invention discloses a traditional Chinese medicine composition for reducing swelling and relieving pain, and its preparation method. The composition comprises the following medicinal ingredients: *Lycopodium clavatum*, *Clematis chinensis*, safflower, ephedra, *Pinus tabuliformis*, *Liquidambar formosana*, *Millettia speciosa*, *Tinospora sinensis*, *Caesalpinia sappan*, *Sparganium stoloniferum* (processed with vinegar), *Curcuma zedoaria*, and *Homalomena occulta*. All ingredients in this composition are natural Chinese herbal medicines, making the raw materials readily available, the preparation method simple, the cost low, and the use convenient. It can be mass-produced. This composition can effectively relieve symptoms of swelling and pain, improve the quality of life, and has high social value.

The present disclosure provides a transparent composition comprising: a. 5-methyl-5 2-(propan-2-yl)phenol, and / or the derivatives, salts and solvates thereof; b. Curcuma zedoaria oil; c. at least one non-ionic surfactant; and d. at least one anionic surfactant having HLB value ≥ 10. The present disclosure also provides method for treating a keratin material, preferably the skin, and use thereof.

The application discloses a kind of Miao medicine composition for treating liver fibrosis and cirrhosis ascites and its preparation method and application, belong to traditional Chinese medicine and national medical technology field.The composition is made of specific weight ratio of chases yellow grass, pearl grass, white flower snake tongue grass, bupleurum, vinegar baked turtle shell, Miao medicine soft liver grass (dried whole grass of gold star fern), catpaw grass, rhizoma sparganii, zedoary, peach kernel, rehmannia, astragalus, atractylodes, angelica, salvia miltiorrhiza, calcined oyster, big belly skin, poria cocos, curcuma, prepared rehmannia, white peony root, chuanxiong.The application provides pill, granule, capsule and the like controllable preparation process, and the product quality is stable, and safety is high.Experiment and clinic confirm that the composition can significantly reverse liver fibrosis, quickly subsides cirrhosis ascites and reduces recurrence rate, simultaneously improves liver function, liver elasticity, serum albumin and blood coagulation function, is suitable for long-term treatment of liver fibrosis and cirrhosis ascites, and has good industrial application prospect.

This invention discloses a drug extract for enhancing the efficacy of porcine reproductive and respiratory syndrome (PRRS) vaccines, its preparation method, and its application. The drug extract comprises aqueous extracts of Astragalus membranaceus and Curcuma zedoaria, wherein the optimal mass ratio of Astragalus membranaceus to Curcuma zedoaria is 4-5:1. The Astragalus membranaceus and Curcuma zedoaria extract of this invention enhances the efficacy of existing PRRSV vaccines, improves vaccine resistance to PRRSV, and effectively stimulates the body to produce sufficient neutralizing antibodies, thereby enhancing the overall immune effect of the vaccine, with significantly better results than using the vaccine alone.

This invention discloses a traditional Chinese medicine composition for treating various cancers and its preparation process, belonging to the field of natural Chinese medicine anti-tumor technology. It aims to address the technical shortcomings and industry gaps of existing anti-cancer Chinese medicines, such as significant toxic side effects, limited intervention scenarios, lack of standardized medication systems, complex processes, and poor recurrence prevention. The composition of this invention consists of ten pure natural and non-toxic raw materials, including Ligusticum chuanxiong, Curcuma zedoaria, and red clover powder. The total weight of a single dose is fixed at 33g, with consistent compatibility requiring no adjustments based on syndrome differentiation. It eliminates toxic medicinal materials and chemical excipients, making it suitable for all solid cancers except leukemia. This invention features a unique three-stage standardized intervention program. This invention can inhibit cancer cell proliferation and metastasis at multiple targets, effectively prevent tumor recurrence, and simultaneously repair the body's immune system and organ damage. It exhibits no drug resistance or cumulative toxicity, possessing advantages such as safety, long-lasting efficacy, broad-spectrum compatibility, standardization, and easy mass production. It effectively fills the gap in pure natural prevention and control technology for the entire cycle of solid cancer, and has extremely high clinical application value.

This invention provides a traditional Chinese medicine preparation for treating Hashimoto's thyroiditis and its preparation method, belonging to the field of traditional Chinese medicine pharmaceutical technology. The preparation is made from Curcuma zedoaria, oyster shell, Eclipta prostrata, Ligustrum lucidum, Sargassum, processed Aconitum carmichaelii, Cremastra appendiculata, Duchesnea indica, Hedyotis diffusa, Artemisia capillaris, Oroxylum indicum, and cinnamon. The formula is meticulously formulated, closely addressing the core pathogenesis of Hashimoto's thyroiditis: "phlegm and blood stasis, spleen and kidney deficiency, and nutritional imbalance." It focuses on "eliminating masses and dispersing nodules, promoting qi and blood circulation," fully embodying the TCM diagnostic and treatment approach of "differentiating syndromes and treating accordingly, addressing both the root cause and symptoms." This invention's preparation has a good therapeutic effect on Hashimoto's thyroiditis, effectively improving thyroid autoimmune disorders, regulating thyroid function, and alleviating symptoms of local thyroid inflammation in experimentally induced Hashimoto's thyroiditis rats. Further clinical observation studies have found that this preparation significantly improves the overall effective rate of clinical treatment for Hashimoto's thyroiditis patients, providing a new approach to the treatment of this condition.

The application discloses a traditional Chinese medicine composition for treating precancerous lesions of atrophic gastritis and a preparation method thereof. Raw material medicines of the traditional Chinese medicine composition are as follows: Astragalus membranaceus, Fructus Mume, Cinnamomum cassia, Curcuma zedoary, raw chicken gizzard, Coptis chinensis and honey-fried licorice. The traditional Chinese medicine composition has remarkable curative effect, has advantages in improving gastric mucosa pathology, endoscopic score, clinical symptoms and syndrome compared with Weifuchun Capsules, a Chinese patent drug commonly used for treating precancerous lesions of atrophic gastritis, and has no obvious adverse reactions and good safety.

This invention pertains to the clinical application of traditional Chinese medicine, primarily focusing on the application of a Chinese herbal extract in the prevention and treatment of endometriosis. The invention also relates to a method for preparing this extract. The preparation method involves: taking 250 g of raw Curcuma zedoaria slices and heating them under reflux with 15 times the volume of 90% ethanol, extracting twice, 1.5 h each time; then extracting the residue with 10 times the volume of distilled water for 1.5 h; combining the ethanol and water extracts, filtering, and concentrating under reduced pressure at 55°C to a crude drug content of 1.93 g / mL. In vivo experiments have demonstrated that the extract significantly reduces the volume of ectopic endometrium. HE staining in nude mice in the endometrial lesion group revealed extensive inflammatory infiltration and angiogenesis in the ectopic endometrial lesions. Administration of the extract significantly reduced inflammatory infiltration and angiogenesis. Immunohistochemical staining of nude mice in the EMs group revealed high positive rates of PCNA and MVD cells. After administration of the herbal extract of this invention, the positive rates of PCNA and MVD cells were significantly reduced, demonstrating a significant anti-endometriosis effect.

The embodiment of the application discloses a traditional Chinese medicine composition for treating hyperlipidemia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperlipidemia is prepared from the following traditional Chinese medicinal materials in parts by weight: 10-30 parts of Coptis chinensis, 20-60 parts of Allium bakeri and 10-30 parts of Curcuma zedoaria. The composition is obtained by refining three medicines from an existing compound preparation based on the theory of 'phlegm and blood stasis' in traditional Chinese medicine. Pharmacodynamic experiments prove that the composition can significantly reduce the levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in serum of hyperlipidemia mice, increase the level of high-density lipoprotein cholesterol (HDL-C), improve liver steatosis and lipid deposition, and has better lipid-lowering and liver-protecting effects than the original compound preparation, is slightly better than the positive drug fenofibrate in increasing HDL-C, and has good application prospect due to refined components, simple preparation process and reduced cost.

The application discloses a traditional Chinese medicine composition for treating triple-negative breast cancer and a preparation method and application thereof. The traditional Chinese medicine composition is composed of Ranunculus japonicus, Alocasia cucullata, centipede, Prunella vulgaris, Curcuma zedoaria, Sparganium stoloniferum, Schisandra chinensis, Euphorbia neriifolia, Solanum nigrum, green calyx, Albizia julibrissin, pericarpium citri reticulatae, Radix Clematidis, Radix Paeoniae Alba, fried Atractylodes, and Rhizoma Belamcandae. The application is aimed at the pathogenesis of triple-negative breast cancer, i.e. liver depression, qi stagnation, phlegm and blood stasis, and deficiency of healthy qi. The whole prescription has the functions of soothing liver and relieving depression, resolving phlegm and removing stasis, promoting blood circulation and removing blood stasis, and supporting healthy qi and resisting cancer. Pharmacodynamic experiments show that the traditional Chinese medicine composition can increase the expression level of DNA damage marker gamma-H2AX, and promote cell apoptosis by inducing DNA damage of tumor cells.

This invention belongs to the field of traditional Chinese medicine preparation technology, specifically involving an extraction process for aromatic water of Wenjing Decoction and a preparation method and application of Wenjing Decoction extract. The extraction process includes (1) taking an appropriate amount of peony bark, adding water and decocting, and collecting aromatic water; (2) adding cinnamon, vinegar-processed turmeric, chuanxiong rhizome and wine-processed angelica root, adding water and decocting, collecting aromatic water, and keeping the dregs for later use; (3) refrigerating the aromatic water collected in step (1) until crystals are completely precipitated, filtering, and collecting the crystals; dissolving the crystals again and combining them with the aromatic water obtained in step (2) to obtain Wenjing Decoction aromatic water. This extraction process uses a specific order of feeding when obtaining Wenjing Decoction aromatic water, ensuring the amount of volatile components obtained, which can be consistent with the traditional Wenjing Decoction decoction, thereby ensuring the safety and effectiveness of the product. The Wenjing Decoction aromatic water of this invention is mainly composed of paeonol and cinnamaldehyde, and the content determination shows that the extraction process of this invention is reliable and has scientific experimental basis.

This invention relates to the field of traditional Chinese medicine, specifically a traditional Chinese medicine composition for improving breast cancer-related dyslipidemia and its application. The composition comprises the following raw materials in parts by weight: Astragalus membranaceus 6-30 parts, Rhodiola rosea 6-30 parts, Curcuma zedoaria 3-15 parts, Polygonatum sibiricum 3-15 parts, and Actinidia chinensis root 1.5-9 parts. This traditional Chinese medicine composition precisely addresses the pathogenesis of qi deficiency and blood stasis after breast cancer surgery, with the entire formula working synergistically to invigorate qi, strengthen the body, and promote blood circulation. Animal experiments have demonstrated that this invention significantly reduces liver index, serum TG, TC, and LDL-C levels in hyperlipidemic mice, with effects comparable to statins. Clinical trials have also confirmed that this invention improves lipid indicators in breast cancer patients with mild dyslipidemia, and has a high safety profile.

This invention discloses a traditional Chinese medicine composition and its application for treating various symptoms caused by spleen deficiency and stomach heat, with warming the spleen yang as the core of the formula. This invention reveals for the first time that modern people, due to excessive intake of animal-based foods, experience excessive stomach heat and a preference for cold foods, repeatedly damaging the spleen yang and forming a pathogenesis of "spleen deficiency and stomach heat," leading to various symptoms such as thirst, dry phlegm, dry and congested nose, obesity or emaciation, and abnormal glucose metabolism. Currently, Western medicine has no radical cure, and traditional Chinese medicine adheres to the theory of diabetes, resulting in poor efficacy. This invention innovatively uses warming the spleen yang as the core of the formula, creating a new formula based on the Da Bu Pi Tang (Great Spleen-Tonifying Decoction) in the *Fu Xing Jue* (Auxiliary Formula). It consists of herbs such as Codonopsis pilosula, prepared licorice root, dried ginger, Ophiopogon japonicus, Schisandra chinensis, Curcuma zedoaria, and Inula japonica. The formula has a rigorous combination of principal, assistant, and adjuvant herbs, warming the spleen without promoting heat and clearing away dampness without harming yang, precisely targeting the pathogenesis of spleen deficiency and stomach heat in modern people. This invention can be formulated into various oral dosage forms, with a simple formula, strong targeting, and high clinical value.

This invention relates to the field of biomedical technology, providing a cascade-responsive, time-controlled release three-layer microsphere. The microspheres are prepared via a W / O / W emulsion method, with a PLGA core simultaneously encapsulating the chemotherapy drug paclitaxel, the traditional Chinese medicine Curcuma zedoaria oil, and an MMP-9 responsive peptide. An outer aqueous phase of sodium alginate provides negatively charged groups. Then, through pH-responsive chitosan electrostatic adsorption, freeze-dried Lactobacillus curvature is directionally anchored to the surface to form a probiotic shell. The microspheres exhibit a three-stage time-series release characteristic: within 0-2 hours, the probiotic shell preferentially colonizes, reducing serum E2 levels and secreting antimicrobial peptides. Within 2-6 hours, the acidic microenvironment regulated by the probiotics triggers a chitosan layer response, releasing Curcuma zedoaria oil to induce ferroptosis in cancer cells and reverse the immunosuppressive microenvironment. Within 6-72 hours, the tumor microenvironment overexpresses enzymatically digested peptides, releasing the core paclitaxel for long-term synergistic killing of tumor cells. This microsphere, through a triple mechanism of "microbial community reconstruction - immune reversal - tumor clearance," synergistically clears tumors and restores microenvironmental homeostasis.

This invention relates to a traditional Chinese medicine composition for treating liver fibrosis and its preparation method. The components or raw materials of this traditional Chinese medicine composition include: 20-30 parts of *Lysimachia christinae*, 8-15 parts of *Trionyx sinensis* shell, 10-16 parts of *Litchi chinensis* seed, 5-15 parts of *Panax notoginseng*, 5-10 parts of *Curcuma zedoaria*, and 8-12 parts of *Poria cocos*. This traditional Chinese medicine composition can be prepared into various pharmaceutical preparations using conventional processes. The components of the above-mentioned traditional Chinese medicine composition are rationally combined, making it a safe and effective treatment for liver fibrosis.

The invention relates to the technical field of biology, and particularly discloses fungus and diatom symbiont microspheres for improving the immune function of cage culture stichopus japonicus and improving water quality. Core functional components of the fungus and diatom symbiont microspheres are cordyceps militaris fungi and Ampelopsis coffee, and in addition, in order to improve the biological activity of the symbiont microspheres and the adhesion of the symbiont microspheres to a netting, pullulan, recombinant mussel mucin, a folium cortex eucommiae extract and a curcuma zedoary extract are also added in the preparation process of the microspheres. The functional components of the symbiont microsphere disclosed by the invention are mutually beneficial, common and synergistic, the non-specific immune function of the stichopus japonicus can be comprehensively improved by enhancing the activity of immune enzyme and digestive enzyme, and meanwhile, the contents of nitrogen phosphorus, nitrite, organic pollutants and pathogenic vibrio in an aquaculture water body can also be reduced.